Comparative Pharmacology
Head-to-head clinical analysis: COLESTID versus LOCHOLEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTID versus LOCHOLEST.
COLESTID vs LOCHOLEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Locholest is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting fecal excretion. This leads to increased hepatic conversion of cholesterol to bile acids, reducing serum LDL cholesterol.
5-10 g orally once or twice daily, maximum 30 g/day.
Initial dose: 10-20 mg orally once daily, taken in the evening. Titrate as tolerated every 4 weeks to a maximum of 80 mg once daily.
None Documented
None Documented
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Terminal elimination half-life is approximately 19 hours (range 14-47 hours) for patients with normal renal function; accumulation occurs with once-daily dosing.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Primarily fecal (biliary) as unchanged drug; renal excretion <5%.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant